Inhibition of UBE2N enhances TRAIL-mediated apoptosis through upregulation of DR5 in cancer cells
International Journal of Medical Sciences · 13.07.2026 · 23 (8) · 2647-2656
DOI: 10.7150/ijms.130235 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medical Sciences, erschienen am 13.07.2026. Verfasst von Yu Jin Jeong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Keimyung University, Daegu 42601, South Korea. Hauptthemen laut MEDLINE: Ubiquitin-Conjugating Enzymes, TNF-Related Apoptosis-Inducing Ligand, Receptors, TNF-Related Apoptosis-Inducing Ligand, Kidney Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Tumor necrosis factor-related apoptosis-induced ligand (TRAIL) selectively induces apoptosis in cancer cells. However, many cancer cells are resistant to TRAIL because of downregulation of death receptors (DRs) and overexpression of anti-apoptotic proteins. Ubiquitin-conjugating enzyme E2N (UBE2N), also known as Ubc13, plays a central role in ubiquitin-mediated cellular activities. In this study, we aimed to explore the sensitization effect of UBE2N inhibition in TRAIL-mediated apoptosis in cancer cells. NSC697923 (a potent inhibitor of UBE2N) alone and TRAIL alone did not induce apoptosis in renal carcinoma Caki cells. However, combined treatment with NSC697923 and TRAIL significantly enhanced apoptotic cell death in cancer cells, but not in normal cells. Mechanistically, NSC697923 induced upregulation of DR5 mRNA and protein levels through CHOP-mediated DR5 transcriptional activation and ubiquitin-mediated DR5 stabilization. NSC697923-mediated DR5 mRNA upregulation was regulated by upregulation of CHOP expression, a key transcriptional factor of DR5. CHOP siRNA treatment inhibited NSC697923-mediated DR5 protein expression. Moreover, NSC697923 generated ROS, and pretreatment with ROS scavengers inhibited DR5 upregulation and NSC697923 plus TRAIL-mediated cell death. These findings suggest that UBE2N inhibitor enhances TRAIL-induced apoptosis by DR5 upregulation and UBE2N inhibition may serve as a potential strategy to overcome TRAIL resistance in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Medicine, Keimyung University, Daegu 42601, South Korea.
- Center for Forensic Pharmaceutical Science, Keimyung University, Daegu 42601, South Korea.
Zitieren
APA
Jeong, Y. J., Woo, S. M., Seo, S. U., Song, S. R., & Kwon, T. K. (2026). Inhibition of UBE2N enhances TRAIL-mediated apoptosis through upregulation of DR5 in cancer cells. International Journal of Medical Sciences, 23(8), 2647-2656. https://doi.org/10.7150/ijms.130235
Vancouver
Jeong YJ, Woo SM, Seo SU, Song SR, Kwon TK. Inhibition of UBE2N enhances TRAIL-mediated apoptosis through upregulation of DR5 in cancer cells. International Journal of Medical Sciences. 2026;23(8):2647-2656. doi:10.7150/ijms.130235
BibTeX
@article{Jeong2026,
author = {Jeong, Yu Jin and Woo, Seon Min and Seo, Seung Un and Song, So Rae and Kwon, Taeg Kyu},
title = {Inhibition of UBE2N enhances TRAIL-mediated apoptosis through upregulation of DR5 in cancer cells},
journal = {International Journal of Medical Sciences},
year = {2026},
volume = {23},
number = {8},
pages = {2647--2656},
doi = {10.7150/ijms.130235}
}
EUVIMED